Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

Core Viewpoint - The Ademi Firm is investigating GMS for potential breaches of fiduciary duty and other legal violations related to its transaction with Home Depot [1][3]. Group 1: Transaction Details - In the tender offer transaction, GMS shareholders will receive $110 per share, leading to a total equity value of approximately $4.3 billion and an implied total enterprise value of around $5.5 billion [2]. - GMS insiders are set to receive significant benefits as part of the change of control arrangements [2]. Group 2: Board Conduct and Shareholder Rights - The transaction agreement imposes significant penalties on GMS for accepting competing bids, which may limit the company's ability to explore better offers [3]. - The investigation focuses on whether the GMS board of directors is fulfilling their fiduciary duties to all shareholders amidst these limitations [3].

MILWAUKEE, June 30, 2025 /PRNewswire/ -- The Ademi Firm is investigating Big 5 (Nasdaq: BGFV) for possible breaches of fiduciary duty and other violations of law in its transaction with Worldwide Golf and Capitol Hill Group.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of Big 5 will receive $1.45 per share, with total enterprise value of ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Krispy Kreme, Inc. securities between February 25, 2025, and May 7, 2025, of the July 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Krispy Kreme securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by July 15, 2025, to serve as lead plaintiff [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Krispy Kreme made false and misleading statements regarding the demand for its products at McDonald's locations, which declined significantly after the initial marketing launch [4]. - It is claimed that the partnership with McDonald's was not profitable and posed substantial risks to maintaining the partnership, leading to a pause in expansion into new locations [4]. - The lawsuit asserts that the positive statements made by Krispy Kreme about its business and prospects were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities between March 21, 2023, and December 9, 2024, of the July 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][4]. Group 1: Class Action Details - Investors who purchased Bitfarms securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 8, 2025 [2][5]. - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to potential misstatements in financial statements [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3].

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

Core Viewpoint - Fortrea Holdings, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding its financial projections and business model viability during the class period from July 3, 2023, to February 28, 2025 [3]. Group 1 - The lawsuit claims that Fortrea overstated projected revenue from Pre-Spin Projects, exaggerated expected cost savings from exiting transition service agreements, and inflated EBITDA targets for 2025 [3]. - Investors are reminded of the August 1, 2025 deadline to seek appointment as lead plaintiff in the class action lawsuit [1][4]. - Wolf Haldenstein Adler Freeman & Herz LLP, the law firm handling the case, has over 125 years of experience in securities litigation and aims to protect the rights of investors [4].